title: Medical management of stable coronary atherosclerosis.
abstract: Revascularisation strategies involving coronary artery bypass grafting or percutaneous interventions are the main treatments for stable coronary artery disease, particularly for patients with ongoing symptoms despite medical therapy and/or extensive ischaemia as demonstrated by either non-invasive or invasive means. Irrespective of whether revascularisation is being undertaken, all patients with stable coronary disease require optimal medical therapy in order to reduce the risk of subsequent adverse cardiac events, particularly acute myocardial infarction. The role of medical management has been very actively investigated and reported, particularly because of the global disease burden and the associated high morbidity and mortality. In this review, the current available medical management for the treatment of coronary atherosclerosis is described together with the role and prospects of the newer classes of drugs that are coming into use, and future perspectives in this field.
authors: Academic Cardiology Unit, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, HU16 5JQ, UK.
authors: P
authors: P
authors: Pellicori
authors: P
authors: P
authors: Costanzo
authors: A C
authors: AC
authors: Joseph
authors: A
authors: A
authors: Hoye
authors: S L
authors: SL
authors: Atkin
authors: J G F
authors: JG
authors: Cleland
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D060050:Angina, Stable / Q000628:therapy*; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000628:therapy*; D004035:Diet Therapy; D015444:Exercise; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D040242:Risk Reduction Behavior; D016540:Smoking Cessation; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents